Table 2. Multivariate evaluation of cohort, race, and tumor type on pCR.

Effect	Adjusted Odds Ratio	95% Confidence Interval	P
Cohort:
Bevacizumab	8.40	1.90–37.1	0.0050
Standard chemotherapy†	1.00	–––––
Race:
African American	4.05	0.99–16.6	0.051
European American†	1.00	–––––
Tumor Type:
Ductal carcinoma	5.37	0.53–54.8	0.16
Other histology†	1.00	–––––

† Reference category